Asciminib Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Updated Results From the AIM4CML Study in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With Prior Tyrosine Kinase Inhibitor (TKI) Treatment

被引：0
|
作者：
Levy, Moshe [1 ]
Andorsky, David [2 ]
Issa, Ghayas [3 ]
Broun, Edward [4 ]
Essell, James [4 ]
Abboud, Camille [5 ]
Damon, Andrea [6 ]
Starinsky, Amy [6 ]
Sadek, Islam [6 ]
Parveen, Naseema [6 ]
Mauro, Michael [7 ]
Deininger, Michael [8 ]
机构：
[1] Baylor Scott & White Hlth, Dallas, TX USA
[2] Rocky Mt Canc Ctr, Boulder, CO USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Oncol Hematol Care, Cincinnati, OH USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Novartis Pharmaceut, East Hanover, PA USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY USA
[8] Univ Utah, Salt Lake City, UT USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CML; AIM4CML; asciminib; CML-CP; oncedaily dosing; twice-daily dosing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-282
引用
收藏
页码：S367 / S367
页数：1
相关论文
共 11 条
  • [1] AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without the T315I Mutation
    Levy, Moshe Y.
    Mauro, Michael J.
    Issa, Ghayas C.
    Andorsky, David
    Tomassetti, Sarah
    Broun, E. Randolph
    Maegawa, Rodrigo
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S298 - S298
  • [2] AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations
    Levy, Moshe Y.
    Mauro, Michael J.
    Issa, Ghayas C.
    Andorsky, David
    Tomassetti, Sarah
    Maegawa, Rodrigo
    Shrestha, Alok
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S334 - S335
  • [3] Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US)
    Atallah, Ehab L.
    Sadek, Islam
    Wei, David
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Damon, Andrea
    Yang, Daisy
    Bellefleur, Remi
    Guerin, Annie
    Jadhav, Kejal
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S365 - S365
  • [4] Trial in Progress: A Phase III Study of Asciminib vs an Investigator-Selected Tyrosine Kinase Inhibitor (TKI) in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hughes, Timothy P.
    Cortes, Jorge
    Takahashi, Naoto
    Larson, Richard
    Issa, Ghayas C.
    Bombaci, Felice
    Ramscar, Nicholas
    Kapoor, Shruti
    Ifrah, Sophie
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S297 - S298
  • [5] Discontinuation of Tyrosine Kinase Inhibitor (TKI) Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in US Clinical Practice Following Updates to NCCN CML Practice Guidelines
    Atallah, Ehab
    Sadek, Islam
    Maegawa, Rodrigo
    Cao, Xiting
    Latremouille-Viau, Dominick
    Pivneva, Irina
    Rossi, Carmine
    Guerin, Annie
    Kota, Vamsi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S231 - S231
  • [6] Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Issa, Ghayas C.
    Larson, Richard A.
    Hughes, Timothy P.
    Hochhaus, Andreas
    Takahashi, Naoto
    Bombaci, Felice
    Wang, Jianxiang
    Kim, Dong-Wook
    Dong, Dennis
    Kim, Hwan
    Gu, Ennan
    Zhang, Yifan
    Kapoor, Shruti
    Agrawal, Nithya
    Jinwal, Rajendra
    Damon, Andrea
    Sadek, Islam
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S368 - S368
  • [7] Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
    Mauro, Michael
    Hochhaus, Andreas
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Apperley, Jane
    Garcia-Gutierrez, Valentin
    Kapoor, Shruti
    Espurz, Noemi
    Dhamal, Vishal
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S340 - S340
  • [8] Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
    Rea, Delphine
    Hochhaus, Andreas
    Mauro, Michael J.
    Minami, Yosuke
    Lomaia, Elza
    Voloshin, Sergey
    Turkina, Anna
    Kim, Wook
    Apperley, Jane F.
    Cortes, Jorge E.
    Abdo, Andre
    Fogliatto, Laura Marie
    Kim, Dennis Dong Hwan
    le Coutre, Philipp
    Saussele, Susanne
    Annunziata, Mario
    Hughes, Timothy P.
    Chaudhri, Naeem
    Chee, Lynette
    Garcia-Gutierrez, Valentin
    Sasaki, Koji
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sara
    Bedoucha, Veronique
    Boquimpani, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S295 - S296
  • [9] Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
    Isfort, Susanne
    Manz, Kirsi L.
    Teichmann, Lino
    Crysandt, Martina
    Burchert, Andreas
    Hochhaus, Andreas
    Saussele, Susanne
    Kiani, Alexander R.
    Gothert, Joachim
    Illmer, Thomas
    Schafhausen, Philippe
    Al-Ali, Haifa Kathrin
    Stegelmann, Frank
    Haenel, Mathias
    Pfeiffer, Tim
    Giagounidis, Aristoteles
    Franke, Georg-Nikolaus
    Koschmieder, Steffen
    Fabarius, Alice
    Ernst, Thomas
    Warnken-Uhlich, Mareille
    Wolber, Uta
    Kohn, Denise
    Pfirrmann, Markus
    Wolf, Dominik H.
    Bruemmendorf, Tim
    German CML Study Grp
    ANNALS OF HEMATOLOGY, 2023, 102 (10) : 2741 - 2752
  • [10] Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
    Susanne Isfort
    Kirsi Manz
    Lino L. Teichmann
    Martina Crysandt
    Andreas Burchert
    Andreas Hochhaus
    Susanne Saussele
    Alexander Kiani
    Joachim R. Göthert
    Thomas Illmer
    Philippe Schafhausen
    Haifa Kathrin Al-Ali
    Frank Stegelmann
    Mathias Hänel
    Tim Pfeiffer
    Aristoteles Giagounidis
    Georg-Nikolaus Franke
    Steffen Koschmieder
    Alice Fabarius
    Thomas Ernst
    Mareille Warnken-Uhlich
    Uta Wolber
    Denise Kohn
    Markus Pfirrmann
    Dominik Wolf
    Tim H. Brümmendorf
    Annals of Hematology, 2023, 102 : 2741 - 2752
12